Experience
Freshworks Agrees to Acquire Device42
May 3, 2024
Cooley advised Freshworks (Nasdaq: FRSH), a company that creates artificial intelligence-boosted business software for IT, customer support, sales, and marketing teams to make them more efficient and deliver more value for immediate business impact, on its agreement and plan of merger with D42 Parent (Device42), pursuant to which Freshworks – through its wholly owned subsidiary, Doppler Merger Sub –will acquire all of the outstanding equity interests of Device42 for an aggregate purchase price of approximately $230 million.Cooley advised Freshworks (Nasdaq: FRSH), a company that creates artificial intelligence-boosted business software for IT, customer support, sales, and marketing teams to make them more efficient and deliver more value for immediate business impact, on its agreement and plan of merger with D42 Parent (Device42), pursuant to which Freshworks – through its wholly owned subsidiary, Doppler Merger Sub –will acquire all of the outstanding equity interests of Device42 for an aggregate purchase price of approximately $230 million.
Related contacts
Related Practices & Industries
Hootsuite to Acquire Talkwalker
April 8, 2024
Cooley advised Hootsuite, a global leader in social media management, on its definitive agreement to acquire Talkwalker, a top artificial intelligence-powered social listening solution.
Related contacts
Related Practices & Industries
ProfoundBio Announces $1.8 Billion Acquisition by Genmab
April 3, 2024
Cooley advised ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate therapeutics for patients with cancer, on its definitive agreement to be acquired for $1.8 billion in an all-cash transaction by Genmab (NASDAQ: GMAB), a dual-listed, international biotechnology company that creates and develops differentiated antibody therapeutics to fight against cancer and other serious diseases.
Related contacts
Related Practices & Industries
Brii Biosciences Announces Agreements to Acquire VBI Vaccines’ IP Rights in BRII-179
February 14, 2024
Cooley advised Brii Biosciences on its agreements with VBI Vaccines (NASDAQ: VBIV) to ensure expansion and control of future clinical and commercial supplies of BRII-179, a late-stage clinical asset in Brii Bio’s hepatitis B virus functional cure portfolio. With operations in major biotechnology centers in the US and China, Brii Bio (HKSE: 2137) is a Hong Kong Stock Exchange-listed biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs.
Related contacts
Related Practices & Industries
Payapps to Be Acquired by Autodesk
January 26, 2024
Cooley advised cloud-based construction software company Payapps and its private equity sponsor IFM Investors on a definitive agreement in which Payapps will be acquired by Autodesk, a multinational software company.
Related contacts
Related Practices & Industries
Related news and events
ChrysCapital Closes Largest Continuation Fund in India, Maintaining Stake in NSE
Admissions & credentials
California
Memberships & affiliations
American Bar Association
Los Angeles County Bar Association
Cooley GO
Start and build your business with our one-stop spot for tips, documents and insights.